Intrafamilial Disease Heterogeneity in Primary Hyperoxaluria Type 1
Lisa J. Deesker(Emma Kinderziekenhuis), Bodo B. Beck(University of Cologne), Michiel J.S. Oosterveld(Emma Kinderziekenhuis), Justine Bacchetta(Université Claude Bernard Lyon 1), Elisabeth L. Metry(Emma Kinderziekenhuis), Larisa Prikhodina(Pirogov Russian National Research Medical University), Laure Collard(Centre Hospitalier Chrétien), Wesley Hayes(Great Ormond Street Hospital), Giorgia Mandrile(University of Turin), Arnaud Devresse(Cliniques Universitaires Saint-Luc), Przemysław Sikora(Medical University of Lublin), Sander F. Garrelfs(Emma Kinderziekenhuis), Cristina Martín-Higueras(Universidad de La Laguna), Olivia Boyer(Hôpital Necker-Enfants Malades), Hazal A. Karacoban(Emma Kinderziekenhuis), Shabbir H. Moochhala(Université Claude Bernard Lyon 1), Sally‐Anne Hulton(Birmingham Children's Hospital), Jaap W. Groothoff(University of Amsterdam), Thomas J. Neuhaus(University of Zurich), Jun Oh(Universität Hamburg)
Cited by 5
Related Papers
The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4
|Nature Genetics|2006|573
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1–SIX1–DNA complexes
|Proceedings of the National Academy of Sciences|2004|420
Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome
|Journal of the American Society of Nephrology|2004|415
TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum
|Nature Genetics|2011|381